The purpose of this study was to determine the role of the combined use of uterine artery Doppler velocimetry (UADV) and maternal serum placental growth factor (PlGF), vascular endothelial growth factor receptor-1 soluble fms-like tyrosine kinase-1 also called soluble (sVEGFR-1), and nitric oxide (NO) products concentrations for the prediction of preeclampsia in high-risk women and to compare these parameters between patients with mild and severe preeclampsia.
Methods:
Patients at risk of preeclampsia (n=112) were subclassified as having either severe (n=38), mild (n=17), or no preeclampsia (n=57). Blood samples were obtained between 22 and 26 weeks of gestation. Doppler ultrasound of the uterine arteries was done at the time of blood sampling. Maternal serum PlGF and sVEGFR-1 concentrations were determined with enzyme-linked immunosorbent assay (ELISA). Nitric oxide colorimetric assay was used also to measure NO products in the maternal blood.
Results:
Among patients with abnormal UADV, maternal serum sVEGFR-1, PlGF, and NO product concentrations contributed significantly in the identification of patients destined to develop mild and severe preeclampsia. sVEGFR-1 (pg/mL) concentration followed by NO product concentration (μmol/L) were found to be the best predictors for preeclampsia, with high sensitivity and specificity, followed by PlGF (pg/mL).
Conclusions:
Abnormal UADV and high concentrations of sVEGFR1 combined with low concentrations of PlGF and NO products may be used to predict the development of preeclampsia.
IrgensHU, ReisaeterL, IrgensLM, LieRT. Long-term mortality of mothers and fathers after pre-eclampsia: Population-based cohort study. BMJ, 2001; 323:1213–1217
3.
FisherSJ, RobertsJM. Defects in placentation and placental perfusion. LindheimerMD, RobertsJM, CunninghamFG. Chelsey's hypertensive disorders in pregnancy. Stamford, CT: Appleton & Lange, 1999; 377–394.
4.
ConradKP, BenyoDF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol, 1997; 37:240–249.
5.
MaynardSE, MinJY, MerchanJet al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest, 2003; 111:649–658.
6.
RinehartBK, TerroneDA, Lagoo-DeenadayalanSet al.Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol, 1999; 181:915–920.
7.
BdolahY, SukhatmeVP, KarumanchiSA. Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Semin Nephrol, 2004; 24:548–556.
8.
KarumanchiSA, BdolahY. Hypoxia and sFlt-1 in preeclampsia: the “chicken-and-egg” question. Endocrinology, 2004; 145:4835–4837.
9.
LamC, LimKH, KarumanchiSA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension, 2005; 46:1077–1085.
10.
WolfM, ShahA, LamCet al.Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol, 2005; 193:16–22.
11.
RanaS, KarumanchiSA, LevineRJet al.Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension, 2007; 50:137–142.
12.
TranquilliAL, BezzeccheriV, GiannubiloSR, ScagnoliC, MazzantiL, GarzettiGG. Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia. Eur J Obstet Gynecol Reprod Biol, 2004; 113:17–20.
13.
AbidM, SchootsI, SpokesK, WuS, MawhinneyC, AirdW. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IκB/NF-κB. J Biol Chem, 2004; 279:44030–44038.
14.
ClarkDE, SmithSK, HeYet al.A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod, 1998; 59:1540–1548.
15.
LevineRJ, MaynardSE, QianCet al.Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 2004; 350:672–683.
16.
KendallRL, WangG, ThomasKA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun, 1996; 226:324–328.
17.
LuF, LongoM, TamayoEet al.Effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol, 2007; 196:e1–e7.
18.
LevineRJ, LamC, QianCet al.Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med, 2006; 355:992–1005.
19.
SladekSM, MagnessRR, ConradKP. Nitric oxide and pregnancy. Am J Physiol Regul Integr Comp Physiol, 1997; 272:R441–R463.
20.
ConradKP. Animal models of pre-eclampsia: Do they exist?Fetal Med Rev, 1990; 2:67–88.
21.
KassabS, MillerMT, HesterR, NovakJ, GrangerJP. Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. Hypertension, 1998; 31:315–320.
StepanH, FaberR, WesselN, WallukatG, SchultheissHP, WaltherT. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab, 2006; 91:2424–2427.
24.
American College of Obstetricians and Gynecologist practice bulletin. Diagnosis and management of preeclampsia and eclampsiaNumber 33, January 2002Obstet Gynecol, 2002; 99:159–167.
25.
BowerS, SchuchterK, CampbellS. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol, 1993; 100:989–994.
26.
SolitroM, Moore SimasT, FrostS, RajanA, CrawfordS, MaynardSE. Circulating soluble fms-like tyrosine kinase-1 (sFlt1) is increased in multiple gestation vs. singleton pregnancies. Presented at the 39th Annual Meeting of the American Society of Nephrology, San Diego, CA, 2006.
27.
Moore SimasTA, CrawfordSL, SolitroMJet al.Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol, 2007; 197:244.e1–244.e8.
28.
EspinozaJ, RomeroR, NienJKet al.Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol, 2007; 196:326.e1–326.e13.
29.
MullerPR, JamesAH, MurthaPP, YonishB, JamisonMG, DekkerG. Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester. Hypertens Pregnancy, 2006; 25:183–192.
30.
Muy-RiveraM, VadachkoriaS, WoelkGB, QiuC, MahomedK, WilliamsMA. Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women. Physiol Res, 2005; 54:611–622.
31.
ChaiworapongsaT, RomeroR, EspinozaJet al.Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol, 2004; 190:1541–1547.
32.
ZhouY, McMasterM, WooKet al.Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol, 2002; 160:1405–1423.
33.
HelskeS, VuorelaP, CarpenO, HornigC, WeichH, HalmesmakiE. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod, 2001; 7:205–210.
34.
RobinsonCJ, JohnsonDD, ChangEY, ArmstrongDM, WangW. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol, 2006; 195:255–259.
35.
TidwellSC, HoHN, ChiuWH, TorryRJ, TorryDS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol, 2001; 184:1267–1272.
36.
DikensoyE, BalatO, PenceS, BalatA, CekmenM, YurekliM. The changes of plasma malondialdehyde, nitric oxide and adrenomedullin levels in patients with preeclampsia. Hypertens Pregnancy, 2009; 28:383–389.
37.
SeligmanSP, BuyonJP, ClancyRM, YoungBK, AbramsonSB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol, 1994; 171:944–948.
